Industry veteran, Amy Verrinder, named VP of Sales
(SAN DIEGO) Sept. 1, 2019 — Cortechs.ai is pleased to announce the appointments of its new chief executive officer, Dr. Chris Airriess, and vice president of sales, Amy Verrinder. Both executives have been long-time employees of Cortechs.ai and have contributed fundamentally to the company’s growth.
Dr. Airriess has been part of the Cortechs.ai team for over 12 years, serving as the company’s chief technology officer and chief operating officer. He was a major catalyst in the development of the flagship product, NeuroQuant®, and came to Cortechs.ai with a wealth of experience guiding product and company development.
Before joining Cortechs.ai, Dr. Airriess oversaw the development and growth of therapeutics designed to combat metastatic melanoma and neuromuscular disorders as the chief operating officer for California Stem Cell. He has also served as a director of scientific computing for the Biomedical Informatics Research Network, headquartered at the University of California San Diego. His past leadership roles and extensive technical background make Dr. Airriess a key driver of the growth and expansion of Cortechs.ai.
Amy Verrinder has over 25 years of experience in business development and has been a strong leader in educating clinicians, researchers and business professionals about the power of volumetric imaging. She previously served as Cortechs.ai’ director of sales and national sales director prior to her appointment as vice president of sales. Amy has brought the workflow enhancements and patient outcome improvements, offered by Cortechs.ai’ suite of products, to dozens of major hospitals and independent imaging facilities across the country. Her deep knowledge of the healthcare industry has allowed her to form strong relationships with stakeholders across North America.
Cortechs.ai has several new initiatives for the remainder of 2019 and beyond. Dr. Airriess and Amy Verrinder both look forward to building upon current momentum as the company continues to deploy innovative solutions to aid in the diagnosis of neurodegenerative diseases and, most importantly, to better patient care.
Cortechs.ai develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of the human brain a routine part of clinical practice. Cortechs.ai’ cutting-edge brain imaging analysis provides neurologists, radiologists and clinical researchers worldwide with a convenient and cost-effective means to quantify subcortical structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma and brain development abnormalities. Please visit cortechs.ai for further information and follow us on Twitter, LinkedIn and Facebook.